We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis’s Entresto Advances Toward Possible New Heart Failure Indication
Novartis’s Entresto Advances Toward Possible New Heart Failure Indication
The FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 12-1 yesterday that study data presented by Novartis to support a new indication for its blockbuster heart failure drug Entresto (sacubitril/valsartan) provided enough evidence.